ANIX — Anixa Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $102.65m
- $80.83m
- $0.21m
- 25
- 17
- 58
- 25
2019 October 31st | 2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.25 | 0 | 0.512 | 0 | 0.21 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 12.1 | 9.98 | 13.6 | 13.9 | 11.2 |
Operating Profit | -11.9 | -9.98 | -13.1 | -13.9 | -11 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -11.8 | -10.1 | -13.1 | -13.8 | -9.93 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11.8 | -10.1 | -13.1 | -13.8 | -9.93 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -11.6 | -10 | -13 | -13.6 | -9.81 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.6 | -10 | -13 | -13.6 | -9.81 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.559 | -0.444 | -0.44 | -0.448 | -0.311 |